Outset Medical 2025 Q3 Earnings Narrowed Losses and Revenue Growth Signal Progress

Outset Medical (OM) reported fiscal 2025 Q3 earnings on November 11, 2025, . , citing delayed large deals and operational challenges. Despite progress in cost-cutting, ongoing financial headwinds and volatility persist.

Revenue

, driven by growth in product and service segments. , . , . The company’s focus on insourced dialysis solutions bolstered demand, though consumables sales were dampened by shifting order patterns.

Earnings/Net Income

, . , . While these reductions highlight operational progress, the company has sustained losses for seven consecutive years, underscoring structural challenges.

Price Action

, , . Post-earnings volatility persisted, .

Post-Earnings Price Action Review

, outperforming the NASDAQ Composite. , , . However, , making this approach suitable only for high-risk-tolerance investors.

CEO Commentary

, . Operational efficiency and forecasting improvements were cited as priorities.

Guidance

, citing delayed orders and consumables demand shifts. , , .

Additional News

Outset Medical faced leadership challenges following the resignation of its head of sales, raising concerns about Q4 execution and deal closure predictability. The company is seeking a new sales leader with expertise in capital equipment and enterprise sales to stabilize operations. Additionally, large console deals initially expected in 2025 H2 were pushed to Q4 2025 and early 2026, further delaying revenue recognition.